We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. (“Leap” or the “Company”) (NASDAQ: LPTX), in connection with the proposed purchase of Flame Biosciences, Inc. (“Flame”).  Under the terms of the merger agreement, the Company will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame shareholders. Upon approval of the transaction, each share of the Series X non-voting convertible preferred stock will be automatically converted into 1,000 shares of common stock.

Weiss Law is investigating whether (i) Leap’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration is fair to Leap’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.